The Spectranetics Corporation (SPNC) : 10 analysts are covering The Spectranetics Corporation (SPNC) and their average rating on the stock is 1.5, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. The Spectranetics Corporation (SPNC) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
The Spectranetics Corporation (SPNC) stock is expected to deviate a maximum of $2.91 from the average target price of $26.46 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $30 and the most muted being $22.
Shares of The Spectranetics Corporation rose by 0.77% in the last five trading days and 15.41% for the last 4 weeks. The Spectranetics Corporation is up 38.02% in the last 3-month period. Year-to-Date the stock performance stands at 66.07%. The Spectranetics Corporation (NASDAQ:SPNC): On Tuesdays trading session , Opening price of the stock was $25.09 with an intraday high of $25.22. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $24.99. However, the stock managed to close at $25.01, a loss of 0.16% for the day. On the previous day, the stock had closed at $25.05. The total traded volume of the day was 155,115 shares.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Companys products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Companys Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.